ACCORDING TO A RECENT ANALYSIS BY HEALTH POLICY RESEARCH FIRM KFF, MORE THAN 3 MILLION MEDICARE BENEFICIARIES COULD NOW BE ELIGIBLE TO RECEIVE COVERAGE FOR WEGOVY, A POPULAR WEIGHT LOSS DRUG THAT HAS RECENTLY BEEN APPROVED IN THE U-S FOR HEART HEALTH. HOWEVER, SOME BENEFICIARIES MAY STILL FACE OUT OF POCKET COSTS FOR THIS EXPENSIVE DRUG, AND SOME MEDICARE PRESCRIPTION DRUG PLANS MAY NOT COVER IT UNTIL 2025. ADDITIONALLY, AS MORE PART D PLANS BEGIN TO COVER WEGOVY, IT'S ALSO WORTH NOTING MEDICARE'S BUDGET MAY ALSO BE AFFECTED.